MovDisordV3, PascalFrancis, Corpus, bibRecord, 000770

Grasping Premanifest Huntington's Disease - Shaping New Endpoints for New Trials

Identifieur interne : 000770 ( PascalFrancis/Corpus ); précédent : 000769; suivant : 000771

Grasping Premanifest Huntington's Disease - Shaping New Endpoints for New Trials

Auteurs : Ralf Reilmann ; Stefan Bohlen ; Thomas Klopstock ; Andreas Bender ; Adolf Weindl ; Philipp Saemann ; Dorothee P. Auer ; Erich B. Ringelstein ; Herwig W. Lange

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:11-0065129

Descripteurs français

Pascal (Inist)
- Chorée de Huntington, Pathologie du système nerveux, Contrôle moteur, Force, Physiologie.

English descriptors

KwdEn :
- Force, Huntington disease, Motor control, Nervous system diseases, Physiology.

Abstract

Future clinical trials in subjects with premanifest Huntington's disease (preHD) may depend on the availability of biomarkers. It was previously shown in symptomatic HD that, the grip force variability coefficient-of-variation (GFV-C) in a grasping paradigm was correlated to the Unified-Huntington's-Disease-Rating-Scale-Total-Motor-Score (UHDRS-TMS) and increased in a 3 year follow-up study. To further elucidate its potential as a biomarker, we investigated whether GFV-C is able to detect a motor phenotype in preHD and is correlated to the genotype assessed by a disease-burden-score. The ability of preHD (n = 15) and symptomatic HD subjects (n = 20) to maintain stable grip forces, while holding an object (250 g and 500 g), was measured and compared with the controls (n = 19). GFV-C was increased in preHD at 500 g, in symptomatic subjects at both weights and was correlated to the disease-burden-score and UHDRS-TMS. GFV-C may be a useful objective and quantitative marker of motor dysfunction across genetically diagnosed premanifest and symptomatic HD subjects.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 16`
A08	`01`	`1`	`ENG`	`@1 Grasping Premanifest Huntington's Disease - Shaping New Endpoints for New Trials`
A11	`01`	`1`		`@1 REILMANN (Ralf)`
A11	`02`	`1`		`@1 BOHLEN (Stefan)`
A11	`03`	`1`		`@1 KLOPSTOCK (Thomas)`
A11	`04`	`1`		`@1 BENDER (Andreas)`
A11	`05`	`1`		`@1 WEINDL (Adolf)`
A11	`06`	`1`		`@1 SAEMANN (Philipp)`
A11	`07`	`1`		`@1 AUER (Dorothee P.)`
A11	`08`	`1`		`@1 RINGELSTEIN (Erich B.)`
A11	`09`	`1`		`@1 LANGE (Herwig W.)`
A14	`01`			`@1 Department of Neurology, University Clinic Muenster (UKM), Westfaelische Wilhelms University of Muenster @2 Muenster @3 DEU @Z 1 aut. @Z 2 aut. @Z 8 aut. @Z 9 aut.`
A14	`02`			`@1 Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University @2 Munich @3 DEU @Z 3 aut. @Z 4 aut.`
A14	`03`			`@1 Department of Neurology, Technical University Munich @3 DEU @Z 5 aut.`
A14	`04`			`@1 Department of Radiology, Max Planck Institute of Psychiatry @2 Munich @3 DEU @Z 6 aut. @Z 7 aut.`
A20				`@1 2858-2862`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000193512620220`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 17 ref.`
A47	`01`	`1`		`@0 11-0065129`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Future clinical trials in subjects with premanifest Huntington's disease (preHD) may depend on the availability of biomarkers. It was previously shown in symptomatic HD that, the grip force variability coefficient-of-variation (GFV-C) in a grasping paradigm was correlated to the Unified-Huntington's-Disease-Rating-Scale-Total-Motor-Score (UHDRS-TMS) and increased in a 3 year follow-up study. To further elucidate its potential as a biomarker, we investigated whether GFV-C is able to detect a motor phenotype in preHD and is correlated to the genotype assessed by a disease-burden-score. The ability of preHD (n = 15) and symptomatic HD subjects (n = 20) to maintain stable grip forces, while holding an object (250 g and 500 g), was measured and compared with the controls (n = 19). GFV-C was increased in preHD at 500 g, in symptomatic subjects at both weights and was correlated to the disease-burden-score and UHDRS-TMS. GFV-C may be a useful objective and quantitative marker of motor dysfunction across genetically diagnosed premanifest and symptomatic HD subjects.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Chorée de Huntington @5 01`
C03	`01`	`X`	`ENG`	`@0 Huntington disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Corea Huntington @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Contrôle moteur @5 09`
C03	`03`	`X`	`ENG`	`@0 Motor control @5 09`
C03	`03`	`X`	`SPA`	`@0 Control motor @5 09`
C03	`04`	`X`	`FRE`	`@0 Force @5 10`
C03	`04`	`X`	`ENG`	`@0 Force @5 10`
C03	`04`	`X`	`SPA`	`@0 Fuerza @5 10`
C03	`05`	`X`	`FRE`	`@0 Physiologie @5 11`
C03	`05`	`X`	`ENG`	`@0 Physiology @5 11`
C03	`05`	`X`	`SPA`	`@0 Fisiología @5 11`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Maladie héréditaire @5 40`
C07	`04`	`X`	`ENG`	`@0 Genetic disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Enfermedad hereditaria @5 40`
C07	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 41`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 41`
N21				`@1 045`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 11-0065129 INIST
ET :	Grasping Premanifest Huntington's Disease - Shaping New Endpoints for New Trials
AU :	REILMANN (Ralf); BOHLEN (Stefan); KLOPSTOCK (Thomas); BENDER (Andreas); WEINDL (Adolf); SAEMANN (Philipp); AUER (Dorothee P.); RINGELSTEIN (Erich B.); LANGE (Herwig W.)
AF :	Department of Neurology, University Clinic Muenster (UKM), Westfaelische Wilhelms University of Muenster/Muenster/Allemagne (1 aut., 2 aut., 8 aut., 9 aut.); Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University/Munich/Allemagn e (3 aut., 4 aut.); Department of Neurology, Technical University Munich/Allemagne (5 aut.); Department of Radiology, Max Planck Institute of Psychiatry/Munich/Allemagne (6 aut., 7 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 16; Pp. 2858-2862; Bibl. 17 ref.
LA :	Anglais
EA :	Future clinical trials in subjects with premanifest Huntington's disease (preHD) may depend on the availability of biomarkers. It was previously shown in symptomatic HD that, the grip force variability coefficient-of-variation (GFV-C) in a grasping paradigm was correlated to the Unified-Huntington's-Disease-Rating-Scale-Total-Motor-Score (UHDRS-TMS) and increased in a 3 year follow-up study. To further elucidate its potential as a biomarker, we investigated whether GFV-C is able to detect a motor phenotype in preHD and is correlated to the genotype assessed by a disease-burden-score. The ability of preHD (n = 15) and symptomatic HD subjects (n = 20) to maintain stable grip forces, while holding an object (250 g and 500 g), was measured and compared with the controls (n = 19). GFV-C was increased in preHD at 500 g, in symptomatic subjects at both weights and was correlated to the disease-burden-score and UHDRS-TMS. GFV-C may be a useful objective and quantitative marker of motor dysfunction across genetically diagnosed premanifest and symptomatic HD subjects.
CC :	002B17; 002B17G
FD :	Chorée de Huntington; Pathologie du système nerveux; Contrôle moteur; Force; Physiologie
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Maladie héréditaire; Pathologie du système nerveux central
ED :	Huntington disease; Nervous system diseases; Motor control; Force; Physiology
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Genetic disease; Central nervous system disease
SD :	Corea Huntington; Sistema nervioso patología; Control motor; Fuerza; Fisiología
LO :	INIST-20953.354000193512620220
ID :	11-0065129

Links to Exploration step

Pascal:11-0065129

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Grasping Premanifest Huntington's Disease - Shaping New Endpoints for New Trials</title>
<author><name sortKey="Reilmann, Ralf" sort="Reilmann, Ralf" uniqKey="Reilmann R" first="Ralf" last="Reilmann">Ralf Reilmann</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Clinic Muenster (UKM), Westfaelische Wilhelms University of Muenster</s1>
<s2>Muenster</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bohlen, Stefan" sort="Bohlen, Stefan" uniqKey="Bohlen S" first="Stefan" last="Bohlen">Stefan Bohlen</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Clinic Muenster (UKM), Westfaelische Wilhelms University of Muenster</s1>
<s2>Muenster</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Klopstock, Thomas" sort="Klopstock, Thomas" uniqKey="Klopstock T" first="Thomas" last="Klopstock">Thomas Klopstock</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University</s1>
<s2>Munich</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bender, Andreas" sort="Bender, Andreas" uniqKey="Bender A" first="Andreas" last="Bender">Andreas Bender</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University</s1>
<s2>Munich</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weindl, Adolf" sort="Weindl, Adolf" uniqKey="Weindl A" first="Adolf" last="Weindl">Adolf Weindl</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Technical University Munich</s1>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Saemann, Philipp" sort="Saemann, Philipp" uniqKey="Saemann P" first="Philipp" last="Saemann">Philipp Saemann</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Radiology, Max Planck Institute of Psychiatry</s1>
<s2>Munich</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Auer, Dorothee P" sort="Auer, Dorothee P" uniqKey="Auer D" first="Dorothee P." last="Auer">Dorothee P. Auer</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Radiology, Max Planck Institute of Psychiatry</s1>
<s2>Munich</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ringelstein, Erich B" sort="Ringelstein, Erich B" uniqKey="Ringelstein E" first="Erich B." last="Ringelstein">Erich B. Ringelstein</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Clinic Muenster (UKM), Westfaelische Wilhelms University of Muenster</s1>
<s2>Muenster</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lange, Herwig W" sort="Lange, Herwig W" uniqKey="Lange H" first="Herwig W." last="Lange">Herwig W. Lange</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Clinic Muenster (UKM), Westfaelische Wilhelms University of Muenster</s1>
<s2>Muenster</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0065129</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 11-0065129 INIST</idno>
<idno type="RBID">Pascal:11-0065129</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000770</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Grasping Premanifest Huntington's Disease - Shaping New Endpoints for New Trials</title>
<author><name sortKey="Reilmann, Ralf" sort="Reilmann, Ralf" uniqKey="Reilmann R" first="Ralf" last="Reilmann">Ralf Reilmann</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Clinic Muenster (UKM), Westfaelische Wilhelms University of Muenster</s1>
<s2>Muenster</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bohlen, Stefan" sort="Bohlen, Stefan" uniqKey="Bohlen S" first="Stefan" last="Bohlen">Stefan Bohlen</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Clinic Muenster (UKM), Westfaelische Wilhelms University of Muenster</s1>
<s2>Muenster</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Klopstock, Thomas" sort="Klopstock, Thomas" uniqKey="Klopstock T" first="Thomas" last="Klopstock">Thomas Klopstock</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University</s1>
<s2>Munich</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bender, Andreas" sort="Bender, Andreas" uniqKey="Bender A" first="Andreas" last="Bender">Andreas Bender</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University</s1>
<s2>Munich</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weindl, Adolf" sort="Weindl, Adolf" uniqKey="Weindl A" first="Adolf" last="Weindl">Adolf Weindl</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Technical University Munich</s1>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Saemann, Philipp" sort="Saemann, Philipp" uniqKey="Saemann P" first="Philipp" last="Saemann">Philipp Saemann</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Radiology, Max Planck Institute of Psychiatry</s1>
<s2>Munich</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Auer, Dorothee P" sort="Auer, Dorothee P" uniqKey="Auer D" first="Dorothee P." last="Auer">Dorothee P. Auer</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Radiology, Max Planck Institute of Psychiatry</s1>
<s2>Munich</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ringelstein, Erich B" sort="Ringelstein, Erich B" uniqKey="Ringelstein E" first="Erich B." last="Ringelstein">Erich B. Ringelstein</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Clinic Muenster (UKM), Westfaelische Wilhelms University of Muenster</s1>
<s2>Muenster</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lange, Herwig W" sort="Lange, Herwig W" uniqKey="Lange H" first="Herwig W." last="Lange">Herwig W. Lange</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Clinic Muenster (UKM), Westfaelische Wilhelms University of Muenster</s1>
<s2>Muenster</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Force</term>
<term>Huntington disease</term>
<term>Motor control</term>
<term>Nervous system diseases</term>
<term>Physiology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Chorée de Huntington</term>
<term>Pathologie du   système nerveux</term>
<term>Contrôle moteur</term>
<term>Force</term>
<term>Physiologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Future clinical trials in subjects with premanifest Huntington's disease (preHD) may depend on the availability of biomarkers. It was previously shown in symptomatic HD that, the grip force variability coefficient-of-variation (GFV-C) in a grasping paradigm was correlated to the Unified-Huntington's-Disease-Rating-Scale-Total-Motor-Score (UHDRS-TMS) and increased in a 3 year follow-up study. To further elucidate its potential as a biomarker, we investigated whether GFV-C is able to detect a motor phenotype in preHD and is correlated to the genotype assessed by a disease-burden-score. The ability of preHD (n = 15) and symptomatic HD subjects (n = 20) to maintain stable grip forces, while holding an object (250 g and 500 g), was measured and compared with the controls (n = 19). GFV-C was increased in preHD at 500 g, in symptomatic subjects at both weights and was correlated to the disease-burden-score and UHDRS-TMS. GFV-C may be a useful objective and quantitative marker of motor dysfunction across genetically diagnosed premanifest and symptomatic HD subjects.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>16</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Grasping Premanifest Huntington's Disease - Shaping New Endpoints for New Trials</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>REILMANN (Ralf)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BOHLEN (Stefan)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KLOPSTOCK (Thomas)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BENDER (Andreas)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>WEINDL (Adolf)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SAEMANN (Philipp)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>AUER (Dorothee P.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>RINGELSTEIN (Erich B.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>LANGE (Herwig W.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, University Clinic Muenster (UKM), Westfaelische Wilhelms University of Muenster</s1>
<s2>Muenster</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University</s1>
<s2>Munich</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, Technical University Munich</s1>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Radiology, Max Planck Institute of Psychiatry</s1>
<s2>Munich</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>2858-2862</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000193512620220</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>17 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0065129</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Future clinical trials in subjects with premanifest Huntington's disease (preHD) may depend on the availability of biomarkers. It was previously shown in symptomatic HD that, the grip force variability coefficient-of-variation (GFV-C) in a grasping paradigm was correlated to the Unified-Huntington's-Disease-Rating-Scale-Total-Motor-Score (UHDRS-TMS) and increased in a 3 year follow-up study. To further elucidate its potential as a biomarker, we investigated whether GFV-C is able to detect a motor phenotype in preHD and is correlated to the genotype assessed by a disease-burden-score. The ability of preHD (n = 15) and symptomatic HD subjects (n = 20) to maintain stable grip forces, while holding an object (250 g and 500 g), was measured and compared with the controls (n = 19). GFV-C was increased in preHD at 500 g, in symptomatic subjects at both weights and was correlated to the disease-burden-score and UHDRS-TMS. GFV-C may be a useful objective and quantitative marker of motor dysfunction across genetically diagnosed premanifest and symptomatic HD subjects.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Chorée de Huntington</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Huntington disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Corea Huntington</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Contrôle moteur</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Motor control</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Control motor</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Force</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Force</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Fuerza</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Physiologie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Physiology</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Fisiología</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie héréditaire</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Genetic disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad hereditaria</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fN21><s1>045</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 11-0065129 INIST</NO>
<ET>Grasping Premanifest Huntington's Disease - Shaping New Endpoints for New Trials</ET>
<AU>REILMANN (Ralf); BOHLEN (Stefan); KLOPSTOCK (Thomas); BENDER (Andreas); WEINDL (Adolf); SAEMANN (Philipp); AUER (Dorothee P.); RINGELSTEIN (Erich B.); LANGE (Herwig W.)</AU>
<AF>Department of Neurology, University Clinic Muenster (UKM), Westfaelische Wilhelms University of Muenster/Muenster/Allemagne (1 aut., 2 aut., 8 aut., 9 aut.); Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University/Munich/Allemagn e (3 aut., 4 aut.); Department of Neurology, Technical University Munich/Allemagne (5 aut.); Department of Radiology, Max Planck Institute of Psychiatry/Munich/Allemagne (6 aut., 7 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 16; Pp. 2858-2862; Bibl. 17 ref.</SO>
<LA>Anglais</LA>
<EA>Future clinical trials in subjects with premanifest Huntington's disease (preHD) may depend on the availability of biomarkers. It was previously shown in symptomatic HD that, the grip force variability coefficient-of-variation (GFV-C) in a grasping paradigm was correlated to the Unified-Huntington's-Disease-Rating-Scale-Total-Motor-Score (UHDRS-TMS) and increased in a 3 year follow-up study. To further elucidate its potential as a biomarker, we investigated whether GFV-C is able to detect a motor phenotype in preHD and is correlated to the genotype assessed by a disease-burden-score. The ability of preHD (n = 15) and symptomatic HD subjects (n = 20) to maintain stable grip forces, while holding an object (250 g and 500 g), was measured and compared with the controls (n = 19). GFV-C was increased in preHD at 500 g, in symptomatic subjects at both weights and was correlated to the disease-burden-score and UHDRS-TMS. GFV-C may be a useful objective and quantitative marker of motor dysfunction across genetically diagnosed premanifest and symptomatic HD subjects.</EA>
<CC>002B17; 002B17G</CC>
<FD>Chorée de Huntington; Pathologie du   système nerveux; Contrôle moteur; Force; Physiologie</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Maladie héréditaire; Pathologie du   système nerveux central</FG>
<ED>Huntington disease; Nervous system diseases; Motor control; Force; Physiology</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Genetic disease; Central nervous system disease</EG>
<SD>Corea Huntington; Sistema nervioso patología; Control motor; Fuerza; Fisiología</SD>
<LO>INIST-20953.354000193512620220</LO>
<ID>11-0065129</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000770 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000770 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:11-0065129
   |texte=   Grasping Premanifest Huntington's Disease - Shaping New Endpoints for New Trials
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Grasping Premanifest Huntington's Disease - Shaping New Endpoints for New Trials

Grasping Premanifest Huntington's Disease - Shaping New Endpoints for New Trials

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri